Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII

Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as os...

Full description

Saved in:
Bibliographic Details
Published inArthritis research & therapy Vol. 25; no. 1; pp. 78 - 10
Main Authors Cheng, Cheng, Huang, Can, Chen, Zhen, Zhan, Feng, Duan, Xinwang, Wang, Yongfu, Zhao, Cheng, Wu, Zhenbiao, Xu, Jian, Li, Hongbin, Yang, Min, Wu, Rui, Zhao, Jiuliang, Zhang, Shangzhu, Wang, Qian, Leng, Xiaomei, Tian, Xinping, Li, Mengtao, Zeng, Xiaofeng
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 12.05.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn. Patients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention.
AbstractList Background Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. Methods SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. Results One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age [less than or equai to] 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI [greater than or equal to] 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn. Conclusion Patients with SLE onset age [less than or equai to] 30, arthritis, existing organ damage (SDI [greater than or equal to] 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention. Keywords: Systemic lupus erythematosus, Avascular necrosis, Risk factors, Risk stratification
Abstract Background Avascular necrosis is a common organ damage in SLE patients, which can influence patients’ life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. Methods SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. Results One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3–6) and low risk (0–2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn. Conclusion Patients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention.
Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn. Patients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention.
BackgroundAvascular necrosis is a common organ damage in SLE patients, which can influence patients’ life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients.MethodsSLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model.ResultsOne hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3–6) and low risk (0–2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.ConclusionPatients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention.
Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients.BACKGROUNDAvascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients.SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model.METHODSSLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model.One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.RESULTSOne hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age ≤ 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI ≥ 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.Patients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention.CONCLUSIONPatients with SLE onset age ≤ 30, arthritis, existing organ damage (SDI ≥ 1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention.
Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients. SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2 years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model. One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2 years. Multi-variate Cox regression analysis suggested that SLE onset age [less than or equai to] 30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI [greater than or equal to] 1) at registration (HR 2.610, p < 0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.
ArticleNumber 78
Audience Academic
Author Li, Hongbin
Cheng, Cheng
Huang, Can
Li, Mengtao
Xu, Jian
Wu, Zhenbiao
Zhan, Feng
Zhao, Cheng
Wu, Rui
Tian, Xinping
Chen, Zhen
Yang, Min
Zhang, Shangzhu
Zeng, Xiaofeng
Wang, Qian
Duan, Xinwang
Wang, Yongfu
Zhao, Jiuliang
Leng, Xiaomei
Author_xml – sequence: 1
  givenname: Cheng
  surname: Cheng
  fullname: Cheng, Cheng
– sequence: 2
  givenname: Can
  surname: Huang
  fullname: Huang, Can
– sequence: 3
  givenname: Zhen
  surname: Chen
  fullname: Chen, Zhen
– sequence: 4
  givenname: Feng
  surname: Zhan
  fullname: Zhan, Feng
– sequence: 5
  givenname: Xinwang
  surname: Duan
  fullname: Duan, Xinwang
– sequence: 6
  givenname: Yongfu
  surname: Wang
  fullname: Wang, Yongfu
– sequence: 7
  givenname: Cheng
  surname: Zhao
  fullname: Zhao, Cheng
– sequence: 8
  givenname: Zhenbiao
  surname: Wu
  fullname: Wu, Zhenbiao
– sequence: 9
  givenname: Jian
  surname: Xu
  fullname: Xu, Jian
– sequence: 10
  givenname: Hongbin
  surname: Li
  fullname: Li, Hongbin
– sequence: 11
  givenname: Min
  surname: Yang
  fullname: Yang, Min
– sequence: 12
  givenname: Rui
  surname: Wu
  fullname: Wu, Rui
– sequence: 13
  givenname: Jiuliang
  surname: Zhao
  fullname: Zhao, Jiuliang
– sequence: 14
  givenname: Shangzhu
  surname: Zhang
  fullname: Zhang, Shangzhu
– sequence: 15
  givenname: Qian
  surname: Wang
  fullname: Wang, Qian
– sequence: 16
  givenname: Xiaomei
  surname: Leng
  fullname: Leng, Xiaomei
– sequence: 17
  givenname: Xinping
  surname: Tian
  fullname: Tian, Xinping
– sequence: 18
  givenname: Mengtao
  surname: Li
  fullname: Li, Mengtao
– sequence: 19
  givenname: Xiaofeng
  surname: Zeng
  fullname: Zeng, Xiaofeng
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37173771$$D View this record in MEDLINE/PubMed
BookMark eNp9kt1q2zAcxc3oWD-2F9jFEOymu3CnT0vezQih6wKBQZpB74Qsy4k620oluSNvtUecnLRbU8bwhcxf5_zEkc5pdtS73mTZWwQvEBLFx4AI5CyHmOSQwALl5EV2gigXeUEKfPTk_zg7DeEWQoxLTF9lx4QjTjhHJ9mvhQ0_QKN0dD6Axnmg7lXQQ6s86I32LtgAbA82KlrTxwB-2rgGYRui6awG7bAZAjB-G9emU9GFIXwCCnRDG22uk8F4oN3a-QhCHOotcA2Yrm1vggHX80uw9EbFLumA6muwSGPl9RpceTdswPn0ejlZfEjjlQ3Rb8HNzWz2OnvZqDaYNw_rWfb9y-Vy-jWff7uaTSfzXLOCxtxwqqDSVFWCo4LwSpuyKRkyTCDYNKZinEOoMGUFqVhdUyhIjbjhuMKUIEzOstmeWzt1KzfedspvpVNW7gbOr6Ty0erWSAEpw4QXouSCUlgLg5GgWtVVQVFtWGJ93rM2Q9WZerwXr9oD6OFOb9dy5e4lgogXJSkT4fyB4N3dYEKUnQ3atK3qjRuCxAIRxkqOx8PeP5PeusH36a5GFSuYwAz-Va1USmD7xqWD9QiVE05LBEu0Y138Q5W-enz91MbGpvmB4d3TpH8iPhYuCcReMFYreNNIbWPqlhuD2zYllmO35b7bMnVb7rotSbLiZ9ZH-n9MvwHFevs8
CitedBy_id crossref_primary_10_3389_fimmu_2024_1288234
crossref_primary_10_3389_fimmu_2024_1381035
crossref_primary_10_1186_s13052_025_01845_8
crossref_primary_10_1016_j_berh_2023_101893
Cites_doi 10.3389/fimmu.2022.1064245
10.1007/s00296-010-1597-9
10.1007/s10067-015-3075-y
10.1136/bmjopen-2020-046163
10.1007/s10753-014-9917-y
10.1007/s11999-010-1292-x
10.1080/08916930400022715
10.1002/art.1780400928
10.1183/13993003.03957-2020
10.1002/art.27236
10.1002/ctm2.526
10.1056/NEJMra071297
10.3389/fmed.2022.847875
10.3109/14397595.2014.987366
10.1093/rheumatology/37.8.895
10.1016/j.semarthrit.2013.05.003
10.1177/0961203306075771
10.2174/1573397117666210907124242
10.1177/09612033211021166
10.1002/acr.24541
10.1177/0961203313500547
10.1016/j.arth.2015.03.036
10.1136/ard.60.12.1145
10.1002/1529-0131(199907)42:7<1405::AID-ANR14>3.0.CO;2-W
10.2478/rir-2021-0001
10.1016/j.autrev.2021.102992
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s13075-023-03061-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals (DOAJ)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
Publicly Available Content Database
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1478-6362
EndPage 10
ExternalDocumentID oai_doaj_org_article_804523768978440d8e2184cadb641de5
PMC10176939
A749109125
37173771
10_1186_s13075_023_03061_3
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
  grantid: 2021-I2M-1-005; 2021-I2M-1-005
– fundername: ;
  grantid: 2021YFC2501300; 2021YFC2501300
– fundername: ;
  grantid: No.Z201100005520022,23, 25-27; No.Z201100005520022,23, 25-27
– fundername: ;
  grantid: 2022-PUMCH-B-013, C-002, D-009; 2022-PUMCH-B-013, C-002, D-009
GroupedDBID ---
.GJ
0R~
23N
2WC
4.4
5GY
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EBD
EBLON
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
HZ~
INH
INR
ITC
KQ8
M1P
O5R
O5S
O9-
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
U2A
UKHRP
WOQ
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
IAO
IHR
NPM
Z7U
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c564t-e74a0ac4ab871637bce9f951e5810ffeb57700a24563b5dd4083d17e72b243123
IEDL.DBID 7X7
ISSN 1478-6362
1478-6354
IngestDate Wed Aug 27 01:27:12 EDT 2025
Thu Aug 21 18:37:32 EDT 2025
Fri Jul 11 16:19:29 EDT 2025
Sat Jul 26 00:01:58 EDT 2025
Tue Jun 17 20:59:32 EDT 2025
Tue Jun 10 20:47:05 EDT 2025
Thu Jan 02 22:51:36 EST 2025
Tue Jul 01 04:01:01 EDT 2025
Thu Apr 24 23:07:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Avascular necrosis
Systemic lupus erythematosus
Risk factors
Risk stratification
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-e74a0ac4ab871637bce9f951e5810ffeb57700a24563b5dd4083d17e72b243123
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2815658250?pq-origsite=%requestingapplication%
PMID 37173771
PQID 2815658250
PQPubID 42876
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_804523768978440d8e2184cadb641de5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10176939
proquest_miscellaneous_2813559725
proquest_journals_2815658250
gale_infotracmisc_A749109125
gale_infotracacademiconefile_A749109125
pubmed_primary_37173771
crossref_citationtrail_10_1186_s13075_023_03061_3
crossref_primary_10_1186_s13075_023_03061_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-05-12
PublicationDateYYYYMMDD 2023-05-12
PublicationDate_xml – month: 05
  year: 2023
  text: 2023-05-12
  day: 12
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Arthritis research & therapy
PublicationTitleAlternate Arthritis Res Ther
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References MC Hochberg (3061_CR10) 1997; 40
CC Mok (3061_CR24) 1998; 37
A Rahman (3061_CR1) 2008; 358
J Zheng (3061_CR22) 2022; 13
P Migliorini (3061_CR27) 2005; 38
KK Zhu (3061_CR25) 2014; 37
MA Mont (3061_CR15) 2015; 30
J Nakamura (3061_CR18) 2010; 28
K Kaneko (3061_CR17) 2021; 11
V Golder (3061_CR9) 2013; 22
J Nakamura (3061_CR13) 2010; 62
K Oinuma (3061_CR3) 2001; 60
R Prasad (3061_CR20) 2007; 16
Q Wei (3061_CR29) 2021; 11
T Kuroda (3061_CR5) 2015; 34
W Fukushima (3061_CR7) 2010; 468
DD Gladman (3061_CR14) 2001; 28
Y Zheng (3061_CR30) 2022; 21
M Sayarlioglu (3061_CR4) 2012; 32
ST Faezi (3061_CR12) 2015; 25
DD Gladman (3061_CR2) 2000; 27
R Kallas (3061_CR16) 2022; 74
M Li (3061_CR11) 2021; 2
EJ Sutton (3061_CR26) 2013; 43
AA Moghazy (3061_CR19) 2022; 18
CE Evans (3061_CR21) 2021; 58
BC Vande Berg (3061_CR6) 1999; 42
T Nevskaya (3061_CR8) 2017; 35
Y Long (3061_CR23) 2021; 30
J Xiong (3061_CR28) 2022; 9
References_xml – volume: 13
  start-page: 1064245
  year: 2022
  ident: 3061_CR22
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.1064245
– volume: 32
  start-page: 177
  issue: 1
  year: 2012
  ident: 3061_CR4
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-010-1597-9
– volume: 34
  start-page: 2071
  issue: 12
  year: 2015
  ident: 3061_CR5
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-015-3075-y
– volume: 11
  start-page: e046163
  issue: 7
  year: 2021
  ident: 3061_CR29
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-046163
– volume: 28
  start-page: 761
  issue: 4
  year: 2001
  ident: 3061_CR14
  publication-title: J Rheumatol
– volume: 37
  start-page: 1852
  issue: 5
  year: 2014
  ident: 3061_CR25
  publication-title: Inflammation
  doi: 10.1007/s10753-014-9917-y
– volume: 468
  start-page: 2715
  issue: 10
  year: 2010
  ident: 3061_CR7
  publication-title: Clin Orthop Relat Res
  doi: 10.1007/s11999-010-1292-x
– volume: 38
  start-page: 47
  issue: 1
  year: 2005
  ident: 3061_CR27
  publication-title: Autoimmunity
  doi: 10.1080/08916930400022715
– volume: 40
  start-page: 1725
  issue: 9
  year: 1997
  ident: 3061_CR10
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780400928
– volume: 58
  start-page: 2003957
  issue: 3
  year: 2021
  ident: 3061_CR21
  publication-title: Eur Respir J.
  doi: 10.1183/13993003.03957-2020
– volume: 62
  start-page: 609
  issue: 2
  year: 2010
  ident: 3061_CR13
  publication-title: Arthritis Rheum
  doi: 10.1002/art.27236
– volume: 27
  start-page: 373
  issue: 2
  year: 2000
  ident: 3061_CR2
  publication-title: J Rheumatol
– volume: 11
  start-page: e526
  issue: 10
  year: 2021
  ident: 3061_CR17
  publication-title: Clin Transl Med
  doi: 10.1002/ctm2.526
– volume: 35
  start-page: 700
  issue: 4
  year: 2017
  ident: 3061_CR8
  publication-title: Clin Exp Rheumatol
– volume: 358
  start-page: 929
  issue: 9
  year: 2008
  ident: 3061_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra071297
– volume: 9
  start-page: 847875
  year: 2022
  ident: 3061_CR28
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2022.847875
– volume: 25
  start-page: 590
  issue: 4
  year: 2015
  ident: 3061_CR12
  publication-title: Mod Rheumatol
  doi: 10.3109/14397595.2014.987366
– volume: 37
  start-page: 895
  issue: 8
  year: 1998
  ident: 3061_CR24
  publication-title: Br J Rheumatol
  doi: 10.1093/rheumatology/37.8.895
– volume: 43
  start-page: 352
  issue: 3
  year: 2013
  ident: 3061_CR26
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2013.05.003
– volume: 16
  start-page: 157
  issue: 3
  year: 2007
  ident: 3061_CR20
  publication-title: Lupus
  doi: 10.1177/0961203306075771
– volume: 28
  start-page: 13
  issue: 1
  year: 2010
  ident: 3061_CR18
  publication-title: Clin Exp Rheumatol
– volume: 18
  start-page: 144
  issue: 2
  year: 2022
  ident: 3061_CR19
  publication-title: Curr Rheumatol Rev
  doi: 10.2174/1573397117666210907124242
– volume: 30
  start-page: 1459
  issue: 9
  year: 2021
  ident: 3061_CR23
  publication-title: Lupus
  doi: 10.1177/09612033211021166
– volume: 74
  start-page: 1122
  issue: 7
  year: 2022
  ident: 3061_CR16
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.24541
– volume: 22
  start-page: 1425
  issue: 13
  year: 2013
  ident: 3061_CR9
  publication-title: Lupus
  doi: 10.1177/0961203313500547
– volume: 30
  start-page: 1506
  issue: 9
  year: 2015
  ident: 3061_CR15
  publication-title: J Arthroplasty
  doi: 10.1016/j.arth.2015.03.036
– volume: 60
  start-page: 1145
  issue: 12
  year: 2001
  ident: 3061_CR3
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.60.12.1145
– volume: 42
  start-page: 1405
  issue: 7
  year: 1999
  ident: 3061_CR6
  publication-title: Arthritis Rheum
  doi: 10.1002/1529-0131(199907)42:7<1405::AID-ANR14>3.0.CO;2-W
– volume: 2
  start-page: 43
  issue: 1
  year: 2021
  ident: 3061_CR11
  publication-title: Rheumatol Immunol Res
  doi: 10.2478/rir-2021-0001
– volume: 21
  start-page: 102992
  issue: 2
  year: 2022
  ident: 3061_CR30
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2021.102992
SSID ssj0022924
Score 2.426808
Snippet Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in...
Background Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors...
BackgroundAvascular necrosis is a common organ damage in SLE patients, which can influence patients’ life quality. Conflicting results exist in risk factors of...
Abstract Background Avascular necrosis is a common organ damage in SLE patients, which can influence patients’ life quality. Conflicting results exist in risk...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 78
SubjectTerms Antibodies
Arthritis
Arthritis - complications
Avascular necrosis
Cohort analysis
Cohort Studies
Complications and side effects
Diagnosis
Drug dosages
East Asian People
Glucocorticoids - adverse effects
Hematology
Humans
Lupus
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - epidemiology
Magnetic resonance imaging
Medical research
Necrosis
Osteonecrosis - diagnosis
Osteonecrosis - epidemiology
Osteonecrosis - etiology
Patients
Pulmonary hypertension
Questionnaires
Registration
Registries
Regression analysis
Rheumatology
Risk Factors
Risk stratification
Statistical analysis
Systemic lupus erythematosus
SummonAdditionalLinks – databaseName: Directory of Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gLonwuFDRISIBQ1CS244TbUrVqEeXQbqW9WY7tlIgqW202h_4rfiIzTrLaCAkuXONJZHvG43nx-A1j73JlMqkqG7kstZGQJosK5RJ0hl7I0pbCeLqcfP49O70SX5dyuVPqi3LCenrgfuIOc-L8xlWQI9wRIna5J1BijSszkTgf2EtxzxvB1AC1UoQV4xWZPDts0VMruonMI4qRk4hPtqHA1v-nT97ZlKYJkzs70Mkj9nAIHWHed3mf3fPNY3b_fDgcf8J-XdTtTxgK6AAGo2DGPFNoPPWjbqFuYKBSbYH-wUJP5VxbuOluuxb8-q7ncV21XfsZDISMw4i65NdA5XTXGwictLCqgKpv-9bD5bdjWIwp62AaB2NGH4SfW_Dh6HIxv_iIj69DeTlYLs_OnrKrk-PF0Wk0FGSIrMzEJvJKmNhYYUqCWVyV1hcVhmhe5klcVb6USsWxobNUXkrnBMZ3LlFepWWKgUrKn7G9ZtX4FwxMxRNhq9JWCoMEh6gxFd7RIZ81heTxjCWjfrQd2MqpaMaNDqglz3SvU4061UGnms_Yp-07tz1Xx1-lv5Dat5LEsx0eoPXpwfr0v6xvxt6T0WjyBtg9a4ZLDThI4tXScyUKol5NUfJgIomr2E6bR7PTgxdpdUpUPhIxPE7H220zvUmZcY1fdUGGEyqkTzzvrXQ7JE4pFkolM5ZP7Hcy5mlLU_8IHOPkqbOCFy__xyy9Yg_SsPZklKQHbG-z7vxrjOU25ZuwbH8DHt1EpA
  priority: 102
  providerName: Directory of Open Access Journals
Title Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII
URI https://www.ncbi.nlm.nih.gov/pubmed/37173771
https://www.proquest.com/docview/2815658250
https://www.proquest.com/docview/2813559725
https://pubmed.ncbi.nlm.nih.gov/PMC10176939
https://doaj.org/article/804523768978440d8e2184cadb641de5
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY9_z1oUbDLYxTP0hWfZeRlpS2rGWkSaQNyFLchdW7CxOHvZf7U-cTpbTmkFf_GCdjcR96O50-h0h73MuM8YrFeosUSFlMgsLrmNrDA1lpSqpNHg5-fwiO53Tbwu28Am31pdV9jbRGWrdKMyRHyYIa8JsPBN9Xf0OsWsUnq76Fhr3yT5Cl6FU88VNwJUUXVNbaiMlu7HS_tJMnh221nZzvJuchug1x2E62Jgcfv__VvrWNjUsoby1J508Jo-8MwnjjvtPyD1TPyUPzv1x-TPyd7psf4FvqQPWPQXZV55CbXAeyxaWNXhw1RYwKwsduPNSwfV2tW3BrP90yK5Nu22_gARXgxjilMwasMHuegMOpRaaCrAft2kNXH6fwKwvYgdZa-hr_MClu-Dj8eVsPP1kX1-5hnOwWJydPSfzk8ns-DT0LRpCxTK6CQ2nMpKKyhIDr5SXyhSVddoMy-OoqkzJOI8iiaeracm0ptbj0zE3PCkT67ok6QuyVze1eUVAVmlMVVWqilu3Qds4MqFG47GfkgVLo4DEPX-E8vjl2EbjWrg4Js9Ex1NheSocT0UakM-7b1Ydesed1EfI9h0lIm-7F836SnhFFjli0FurnNvwm9JI5waDZCV1mdFYGxaQDyg0Au2DnZ6S_pqDXSQibYkxpwWCsSaW8mBAafVaDYd7sRPerrTiRgsC8m43jF9irVxtmq2jSTFOxF-87KR0t6QUiy44jwOSD-R3sObhSL386VDH0XZnRVq8vnteb8jDxGkVC-PkgOxt1lvz1vptm3LklHNE9o8mFz-mI5f9sM95Mv4HpppC0g
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIQEviG8KAw4JBAhFy4cdJ0gIlbGpZd0etk7qm3EcZ1RMaWlaof1TiD-ROyfpFiHtbW9R7ES27nx3P_v8O8ZeJ1LHQhbGy-PQeFzo2EtlHqAxtFxkJuPa0uXkg8N4cMK_TcRkg_1p78JQWmVrE52hzmeG9si3Q6I1EYhn_M_zXx5VjaLT1baERq0W-_b8N0K26tPwK8r3TRju7Y53Bl5TVcAzIuZLz0qufW24zggrRDIzNi0wzrAiCfyisJmQ0vc1HQhGmchzjkFKHkgrwyxEb0tEB2jyb-CjT2BPTi4AXpjWRXQ5IjN05Ly9pJPE2xX6Ckl3oSOPovTAizqO0NUL-N8rXHKL3ZTNSz5w7y670wSv0K-17R7bsOV9dvOgOZ5_wP4eTauf0JTwAQyHQbeZrlBaGse0gmkJDZlrBbQLDDWZ9NTA2Wq-qsAuzmsm2Vm1qj6CBpfz6NGQ7AKooO9iCY4VF2YFUP1vW1k4Hu3CuE2aB13m0OYUgtteg3c7x-P-0Xt8feoK3MFkMhw-ZCfXIrxHbLOclfYJA11EATdFZgqJYUqOuDXkNqdjRqNTEfk9FrTyUabhS6eyHWfK4aYkVrVMFcpUOZmqqMc-rL-Z12whV_b-QmJf9ySmb_ditjhVjeFQCXHeoxdIEO5z7ueJJVBudJ7FPMit6LG3pDSK7BEOz-jmWgVOkpi9VF_ylMhfQ-y51emJdsR0m1u1U40dq9TFquuxV-tm-pJy80o7W7k-EeFS-sXjWkvXU4ooyUPKoMeSjv525txtKac_HMs5-Yo4jdKnV4_rJbs1GB-M1Gh4uP-M3Q7dChNeEG6xzeViZZ9jzLjMXriFCuz7dVuGf4PqeyU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+for+avascular+necrosis+in+patients+with+systemic+lupus+erythematosus%3A+a+multi-center+cohort+study+of+Chinese+SLE+Treatment+and+Research+Group+%28CSTAR%29+Registry+XXII&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Cheng%2C+Cheng&rft.au=Huang%2C+Can&rft.au=Chen%2C+Zhen&rft.au=Zhan%2C+Feng&rft.date=2023-05-12&rft.issn=1478-6362&rft.eissn=1478-6362&rft.volume=25&rft.issue=1&rft.spage=78&rft_id=info:doi/10.1186%2Fs13075-023-03061-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon